Mark Lawler, PhD, Leader of the Lancet Oncology European Groundshot Commission, and Professor of Digital Health at Queen’s University Belfast, discusses data from the European Groundshot Report, which identified some improvements for mortality in Hodgkin lymphoma, but also identified unfavorable trends for multiple myeloma and non-Hodgkin lymphoma. Dr. Lawler discussed the insights gained from this data and how it can shape the future of cancer care in Europe.